"94-96%"@en . . . . . "Rapidly and completely absorbed."@en . "alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide"@en . . . . . "In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia."@en . . . . . . . . . "4'-Nitro-3'-trifluoromethylisobutyranilide"@en . . "Humans and other mammals"@en . . . . "FTA"@en . . "Flutamide"@en . "Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours."@en . . "Eulexin"@en . . . "Flutamida"@en . . . . . . "Jack Lawrence James, Louis Frank Molnar, Jr., Tania E. Toney-Parker, \"Processes for preparing flutamide compounds and compounds prepared by such processes.\" U.S. Patent US 6,228,401, issued November, 1976."@en . . . . . . "Niftolid"@en . . . . "For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate"@en . . . . . . . "Flutamid"@en . . "Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen."@en . . . . . . "NFBA"@en . . . . "An antiandrogen with about the same potency as cyproterone in rodent and canine species."@en . . . . . "13311-84-7"@en . . "Niftolide"@en . . "# \"Link\":http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm"@en . . . . . . " "@en . . "The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours."@en . . "Take without regard to meals."@en . . "Flutamidum"@en . . "approved"@en . . "Flutamide"@en . . .